Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 15/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845458 | 0.88 | CYP2C9 (0.49) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4040946 | 0.84 | CYP2C9 (0.63) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4040558 | 0.69 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6635038 | 0.67 | CYP2C9 (0.61) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4046348 | 0.65 | CYP2C9 (0.67) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4039707 | 0.64 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4037773 | 0.64 | CYP2C9 (0.62) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4037854 | 0.63 | CYP2C9 (0.61) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6183408 | 0.63 | CYP2C9 (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4039005 | 0.62 | CYP2C9 (0.61) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.